Plasmalemmal vesicle‐associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor‐A (VEGF)
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor‐A (VEGF) is an important regulator of vascular permeability. In preclinical studies, VEGF induces endothelial fenestrations in pre‐existing and neo‐vasculature, while inhibition of VEGF leads to a reduction in endothelial fenestrations. Recently, vascular regression in response to VEGF inhibition has been shown to correlate with the presence of endothelial fenestrations. Plasmalemmal vesicle‐associated protein (PLVAP) is believed to be a component of diaphragmed endothelial fenestrations, but a direct relationship with VEGF signalling has not been established. The aim of this study was to characterize the expression pattern of PLVAP and investigate whether PLVAP is a transcriptional target of VEGF signal transduction. The expression pattern of PLVAP was characterized in normal and neoplastic human tissues by in situ hybridization and/or immunohistochemistry. The role of VEGF signal transduction in the regulation of PLVAP expression was investigated in vitro using receptor‐selective engineered forms of VEGF, a neutralizing monoclonal antibody against VEGF, and inhibitors of downstream signalling pathways. PLVAP mRNA and protein were widely expressed in the endothelium of normal and neoplastic tissues. In cultured endothelial cells, VEGF signalling through receptor 2 stimulated expression of PLVAP total RNA and protein. This induction could be blocked with an anti‐VEGF monoclonal antibody and by inhibitors of phosphatidylinositol 3‐kinase (LY294002) or p38 mitogen‐activated protein kinase (SB203580), but not by PD98059, a mitogen‐activated protein/extracellular signal‐regulated kinase 1 inhibitor. These data show that PLVAP is more widely expressed in the vasculature of normal tissues than previously thought and that it is expressed in the vasculature of most human tumours. We suggest that PLVAP is a downstream target of VEGF signalling. This work solidifies the association between VEGF and the appearance and maintenance of fenestrations by providing a potential mechanistic link. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“The association between VEGF, angiogenesis and tumour progression is well documented and many anti-angiogenic strategies are currently being used and tested in the clinic [58].”
BackgroundRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., & Comoglio, P. M. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.629 · Cited by 1,337 · cited 1×
“The addition of bFGF, VEGF, HGF and PlGF to HUVECs for 24 h increased the activity of the cells compared to controls (Figure 3A) as previously described [37,38].”
MethodTargeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743 · cited 2×
“VEGF is an important mediator of increased vascular permeability [1–5], a characteristic of tumourassociated vasculature [2,6,7], and has been reported to induce intracellular transcytosis [2,4].”
BackgroundResult
Cited by
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
Qian, J., Olbrecht, S., Boeckx, B., Vos, H., Laoui, D., Etlioglu, E., Wauters, E., Pomella, V., Verbandt, S., Busschaert, P., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0355-0 · Cited by 817
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Klaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Sharma, A., Seow, J. J. W., Dutertre, C.-A., Pai, R., Blériot, C., Mishra, A., Wong, R. M. M., Singh, G. S. N., Sudhagar, S., Khalilnezhad, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.040 · Cited by 677
Norrin/Frizzled4 Signaling in Retinal Vascular Development and Blood Brain Barrier Plasticity
Wang, Y., Rattner, A., Zhou, Y., Williams, J., Smallwood, P. M., & Nathans, J. (2012) · Cell · doi:10.1016/j.cell.2012.10.042 · Cited by 406
The role of VEGF receptors in angiogenesis; complex partnerships
Cébe-Suarez, S., Zehnder-Fjällman, A., & Ballmer-Hofer, K. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5426-3 · Cited by 405
Satchell, S. C., & Braet, F. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90601.2008 · Cited by 347
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Self-citationThe inner blood-retinal barrier: Cellular basis and development
Díaz-Coránguez, M., Ramos, C., & Antonetti, D. A. (2017) · Vision Research · doi:10.1016/j.visres.2017.05.009 · Cited by 314
Blanchard, J. W., Bula, M., Davila-Velderrain, J., Akay, L. A., Zhu, L., Frank, A., Victor, M. B., Bonner, J. M., Mathys, H., Lin, Y.-T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0886-4 · Cited by 283
Sorribas, M., Jakob, M. O., Yilmaz, B., Li, H., Stutz, D., Noser, Y., de Gottardi, A., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.017 · Cited by 253
Metadata
- Authors
- Strickland, L. A., Jubb, A. M., Hongo, J., Zhong, F., Burwick, J., Fu, L., Frantz, G. D., & Koeppen, H.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2005-06-21
- Volume
- 206
- Issue
- 4
- Pages
- 466-475
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1968070105
- Cited by
- 116
- References
- 6
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.